PFS Significantly Improves With Acalabrutinib Regimen in Untreated CLL
Acalabrutinib-based treatment also improves overall survival vs standard chemoimmunotherapy in the phase 3 AMPLIFY trial.
Related Articles
Transparency and Consolidation Issues Hamper 340B Program in Cancer Care
Since it’s implementation in 1992, the aim of the 340B Drug Pricing Program has been to offer low-income and underserved patient populations with cancer and…
Preparation is Key to Tackle the Transition from Fellow to Attending Physician
A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.
Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care
Carol Aghajanian, MD, has stayed at the forefront of innovation in gynecologic oncology—and she credits her patients and their conversations in retaining that role.
Tarlatamab Earns UK Approval for Previously Treated ES-SCLC
Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.
Cancer statistics, 2025
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data…
Imetelstat Plus Ruxolitinib Demonstrates Tolerable Safety Profile in Myelofibrosis
Imetelstat plus ruxolitinib showed early tolerability and efficacy in patients with intermediate and high-risk myelofibrosis.
Anito-Cel Demonstrates Safety and Early Efficacy in R/R Multiple Myeloma
Anitocabtagene autoleucel generated durable response in patients with relapsed/refractory multiple myeloma.
Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: a population-based study
Urgent strategies are required to empower the global health-care workforce and facilitate the fundamental human right of access to suitable health care. A collective effort…
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and…
CGSO Board Exam Review Course – Society of Surgical Oncology
Registration is open for the next CGSO Board Exam Review Course taking place on January 25, 2025. Register Now View Course Agenda Learn more about…
